INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,575,742 | -18.0% | 87,843 | -0.4% | 0.39% | -16.5% |
| Q2 2023 | $5,583,368 | +13.2% | 88,177 | -3.2% | 0.47% | +8.8% |
| Q1 2023 | $4,932,849 | +1.1% | 91,096 | -1.2% | 0.43% | -3.2% |
| Q4 2022 | $4,877,689 | -5.0% | 92,171 | +2.4% | 0.44% | -32.7% |
| Q3 2022 | $5,137,000 | +0.2% | 89,994 | +0.2% | 0.66% | +35.8% |
| Q2 2022 | $5,128,000 | -7.5% | 89,844 | -0.8% | 0.49% | -22.5% |
| Q1 2022 | $5,542,000 | +18.9% | 90,544 | +1.7% | 0.63% | +15.9% |
| Q4 2021 | $4,661,000 | – | 89,051 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |